AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata

After Phase 3 results show major hair regrowth gains

AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease

The submission is backed by positive results from the Phase 3 AFFIRM study

AbbVie bets $1.4B on North Carolina pharma mega-campus

Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing

Why secure, empathetic home care defines the next era of healthcare delivery: Suhasini Deshmukh, Co-founder, MedRabbits

Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs

AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial

Highlights Mirvetuximab-based regimen promise

Abbott launches nationwide Vitamin C awareness campaign

The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day

AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit

Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims

MedRabbits launches integrated clinic to revolutionize patient care

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes

This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin

AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks